干扰素中和抗体与乙肝病毒DNA含量的关系

The relationship between neutralizing antibody to IFNα-2b and the serum HBV DNA content

目的 :了解干扰素中和抗体对干扰素疗效的影响。方法 :用中和生物法检测 6 4例慢性乙型肝炎 (CHB)患者干扰素治疗前后血清的干扰素中和抗体 (NA) ,同时用荧光定量PCR技术检测干扰素治疗前后血清HBVDNA的含量。结果 :6 4例接受干扰素治疗的CHB患者中 2 1例患者治疗后检出NA (32 .81% ) ,治疗前后的血清HBVDNA含量在NA阳性组无显著性差异 (P >0 .0 5) ,在NA阴性组有显著性差异 (P <0 .0 5)。 2 1例NA阳性者在治疗结束时 1例 (4 76 % )患者血清中HBVDNA被清除 ,4 3例NA阴性者在治疗结束时 16例 (37.2 1% )患者血清中HBVDNA被清除 ,二者比较P <0 .0 1。结论 :NA能影响干扰素的疗效 ,并可作为预测干扰素疗效的指标。

Aim: To study the effect of neutralizing antibody on the therapeutic effect of IFNα-2b.Methods: Antiviral neutralization assay were used to detect neutralizing antibody against IFN in the sera from 64 patients with chronic hepatitis B. At the same time, HBV DNA was quantitated in sera at the beginning and end of treatment with a quantitative PCR assay which was based on Amplisensor assay.Results: The neutralizing antibody against IFN was found in 21 of 64 patients(32.81%)who had been treated with IFNα-2b. The content of HBV DNA in sera at the beginning and the end of therapy was of no statistical difference in the NA positive patients ( P >0.05); but there was significant difference in the NA negative patients ( P <0.05). At the end of IFN therapy, HBV DNA was cleared away in 1 of 21 (4.76%) NA positive patients while in 16 of 43(37.21%) NA negative patients ( P >0.01). Conclusion: It indicated that neutralizing antibody can affect the response to IFN therapy, detection of NA is one of the methods that would predict the therapeutic effect of IFN.